Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
If Viking Therapeutics Is Acquired, Here’s Who Wins
08:50am, Tuesday, 26'th May 2026
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with a
Novo Nordisk and Eli Lilly Just Delivered Potential Breakthrough for Cancer Patients
08:25am, Tuesday, 26'th May 2026
Novo Nordisk (NVO) and Eli Lilly (LLY) may have an additional growth story on their hands after a new set of studies suggested GLP-1 medicines could help cancer
Is NVO Undervalued? DCF Says Worth $90
07:42am, Tuesday, 26'th May 2026
On May 26, 2026, we present a discounted cash flow (DCF) analysis for Novo Nordisk AS (NVO), a company currently facing a challenging price performance with a y
New results from the landmark POSEIDON real-world evidence study at EAS Congress: 2 in 5 people with CVD have CV inflammation - higher risk of heart attack
CHMP Backs EU Approval of Novo Nordisk's Wegovy Pill for Obesity
12:01pm, Monday, 25'th May 2026
NVO's Wegovy pill gets CHMP backing, moving it closer to becoming the first oral GLP-1 treatment approved in the EU for weight management.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
10:01am, Monday, 25'th May 2026
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.
05:05am, Monday, 25'th May 2026
Eli Lilly and Novo Nordisk have been vying for dominance in the weight loss drug market. Lilly has gradually surpassed Novo Nordisk, and it now holds 60% of the U.S. market.
Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)
01:30pm, Friday, 22'nd May 2026
Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU Novo Nordisk expects to launch Wegovy® 7.2 mg in a single-dose pen in the EU in Q3 2026 In the STEP UP tri
Novo Nordisk faces new GLP-1 rival as Eli Lilly's triple agonist sets weight-loss record
12:04pm, Friday, 22'nd May 2026
Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a...
Novo Nordisk faces new GLP-1 rival as Eli Lilly's triple agonist sets weight-loss record
11:11am, Friday, 22'nd May 2026
Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of t
Novo Nordisk uses AI to fast-track drug launches, expand India role
09:11am, Friday, 22'nd May 2026
Novo Nordisk is aiming to slash the time it takes to bring new drugs to market by up to two-thirds using AI, a top executive said, as the Danish drugmaker looks to regain momentum in the booming
With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP-1 treatment recommended by CHMP for weight management in the EU. CHMP recomme
European Regulator Backs Novo Nordisk's Wegovy Weight-Loss Pill
08:30am, Friday, 22'nd May 2026
The recommendation paves the way for it to become the first tablet approved to treat obesity in the European Union.
European medicines regulator recommends approval for Novo's Wegovy pill
06:47am, Friday, 22'nd May 2026
The European Medicines Agency recommended approval for Novo Nordisk's weight-loss pill Wegovy, the regulator said on Friday, clearing its path to become the first oral �
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
12:36pm, Thursday, 21'st May 2026
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
